Skip to content

Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast Enhancement

Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI: Development and Clinical Validation of a Diffusion-Weighted Imaging-Based Synthetic Contrast-Enhanced MRI System for Non-Contrast Breast Cancer Diagnosis and Risk Stratification

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07598084
Enrollment
12000
Registered
2026-05-20
Start date
2026-06-01
Completion date
2027-05-01
Last updated
2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Artificial Intelligence (AI), Breast Neoplasms, Deep Learning, Diffusion Magnetic Resonance Imaging, Magnetic Resonance Imaging (MRI)

Keywords

Breast, Magnetic Resonance Imaging, Artificial Intelligence, Deep learning

Brief summary

This study is conducted under the ethics-approved project titled "Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI''.The goal of this observational study is to develop an integrated breast MRI system that uses diffusion-weighted imaging (DWI) to create synthetic contrast-enhanced images. This system aims to diagnose and screen for breast cancer without the need for contrast agents, while using a generated risk score to perform imaging-based triage and risk stratification. Participants will include people aged 18 and older who require a breast MRI either for evaluation of a suspicious finding or for high-risk screening. This study seeks to answer two main questions: * Can synthetic contrast-enhanced images generated from DWI match real contrast-enhanced images in their ability to distinguish benign from malignant breast lesions? * Can the risk score derived from DWI-based synthetic images enable imaging-level risk stratification, allowing people at lower risk to avoid contrast agent injection? Researchers will compare the quality of synthetic images against real contrast-enhanced images and will recruit radiologists to assess how well these images perform for diagnostic and screening tasks. MRI data from participants undergoing breast MRI will be used to train, validate, and test this integrated system.

Detailed description

We selected "other" in Time Perspective. This study will retrospectively collect MRI data from patients who underwent breast MRI at multiple centers between 2014 and 2024. We will also prospectively enroll MRI data from multiple centers for testing to assess the model's robustness.

Interventions

DIAGNOSTIC_TESTNon-contrast breast MRI diagnostic model

An integrated AI model capable of generating synthetic contrast-enhanced images and distinguishing between benign and malignant lesions, as well as performing risk stratification

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Complete breast MRI data; 2. Negative pathology biopsy results or negative follow-up examinations for at least 12 months for non-cancer cases; 3. Positive biopsy results that meet the requirements for the pathological subtype of cancer for cancer cases; 4. Original data that can be used to verify clinical status, including radiological and pathological reports;

Exclusion criteria

1. Partial mastectomy or puncture biopsy on the diseased side of the breast prior to breast MRI examination; 2. Poor image quality; 3. Implants in the affected breast;

Design outcomes

Primary

MeasureTime frameDescription
MRI examinationBaselineA multi-parameter contrast-enhanced breast MRI examination was performed, including fat-suppressed T2-weighted imaging, diffusion-weighted imaging, dynamic contrast-enhanced sequences, and fat-suppressed T1-weighted imaging.

Contacts

CONTACTHAOQUAN CHEN, MD
CHENHAOQUANSZ@163.COM+86 010-88325811

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 10, 2026